Johannes van der Loo, PhD
Title
Director, Aseptic Processing Laboratories
Director, Vector Production Facility
Director, Research Viral Vector Core
Appointment
Field Service Associate Professor
Email
Han.vanderloo@cchmc.org
Phone
513-803-1066
Fax
513-636-1446
Bio
Dr. van der Loo has been employed by CCHMC since 2002 where he is the Director of the CCHMC Aseptic Processing Laboratories, an ISO Class 7 and 8 cleanroom facility for the manufacture of GMP-grade viral vectors and manipulation of GMP/GTP-grade cellular products for phase I/II Clinical Trials in compliance US federal and European guidelines. In addition, he is the Director of the Vector Production Facility, the Director of the Research Viral Vector Core and the Chair of the CCHMC Institutional Biosafety Committee (IBC). His previous appointment as Assistant Professor (1998-2002) was with the Department of Hematology/Oncology and Transplantation, at the University of Minnesota School of Medicine, in Minneapolis, MN.
Dr. van der Loo is the Director of the Cincinnati Children's Hospital Medical Center's Vector Production Facility and Viral Vector Core.
Credentials
BS: Biology, State University of Utrecht, the Netherlands, 1983.
MS: Medical Biology, State University of Utrecht, the Netherlands, 1987.
Teaching degree: Biology, State University of Utrecht, Netherlands, 1989.
PhD: Hematology, Erasmus University Rotterdam, the Netherlands, 1995.
Postdoctoral Fellowship: Hematology, Howard Hughes Medical Institute, Indiana University, Indianapolis, IN, 1994-1998.
Position History
2002– Director, Vector Production Facility and Assistant Professor, Division of Experimental Hematology, Children's Hospital Research Foundation, Cincinnati, OH
1998–2002 Assistant Professor, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, MN
1994–1998 Research Associate, Howard Hughes Medical Institute, Indiana University School of Medicine, Indianapolis, IN
1989–1994 PhD Student, Erasmus University, Rotterdam, the Netherlands
1987–1989 Research Associate, National Institute for Public Health and Environmental Hygiene, Bilthoven, the Netherlands
Research
In 2008 the research Viral vector Core (VVC) supplied vector to 31 different investigators with a total of 3100 viral vector products delivered since it's inception in 2004. This includes investigators from Ohio State University, Nationwide Children's Hospital, University of Cincinnati, Indiana University, and University of Louisville. The VPF and VVC moved to expanded facilities in Building S at CCHMC in 2008 and will continue to provide both GMP and research-grade product to investigators using a fee-for-service model.
Research Grants and Contracts
Contract with a private Biotech (name withheld) for GMP production of an AAV vector for a phase I clinical trial (2009).
Contract with a private Biotech (name withheld) for GMP production of an AAV2 vector for a phase IIB clinical trial (2009).
Contract with Nationwide Children’s Hospital for the GMP manufacture of a Master Viral Bank (2009).
SPR106038 Translational Research Initiative (TRI) award (2009): Novel Molecular Therapy Core (Vanderloo, PI).
Agreement with CCHMC for the GMP production of a lentiviral vector for a phase I clinical trial for Sickle Cell Anemia (2009)
Contract with industry in support of a clinical trial sponsored by Solving Kids Cancer (2009).
Publications, Most Recent
Connect to Han van der Loo's publications on PubMed
Carey B, Staudt MK, Bonaminio D, Van der Loo JCM, and Trapnell BC (2007). PU.1 redirects adenovirus to lysosomes in alveolar macrophages, uncoupling internalization from infection. J Immunol 178, 2440-2447.
Suzuki, T., Sakagami, T., Rubin, B.K., Nogee, L.M., Wood, R.E., Zimmerman, S.L., Smolarek, T., Dishop, M.K., Wert, S.E., Whitsett, J.A., Grabowski, G., Carey, B.C., Stevens, C., van der Loo, J.C.M., And Trapnell, B.C. (2008). Familial Pulmonary Alveolar Proteinosis Caused by Mutations in CSF2RA. J Exp Med 205, 2703-2710.
Schambach, A., Swaney, W.S., and van der Loo, J.C.M. 2009. Design and production of retro- and lentiviral vectors for gene expression in hematopoietic cells. In Methods in Molecular Biology. C. Baum, editor: Totowa, NJ: Humana Press. 191-205.
Presentations, Most Recent
Retrofitting Non-Cleanroom Spaces into GMP Cleanrooms in an Academic Medical Center. Lilith Reeves and Johannes C.M. van der Loo. Facilities for Mammalian Cell Products, From Design Through Operation, Williamsburg Bioprocessing Foundation, Philadelphia, PA, October, 2005.
Axel Schambach, Melanie Galla, Tobias Maetzig, Daniela Zychlinski, Ute Modlich, Michael Milsom, Elke Grassman, Anjali Mishra, Johannes C.M. van der Loo, David Williams, Susannah Bailey, Adrian Thrasher, Christopher Baum. Retroviral SIN vector platform: From basic biology to clinical application. German Society of Gene Therapy (DG-GT) 14th Annual Meeting, July 17-20, 2007.
Johannes C.M. van der Loo, William P. Swaney, Diana L. Nordling, Axel Schambach, Christopher Baum, David A. Williams, Punam Malik, and Lilith Reeves. Production of Retroviral Vectors by Transfection in a Closed System Bioreactor. Invited speaker at the Viral Vectors & Vaccines conference in Austin, TX, Oct 29-31, 2007.
Johannes C.M. van der Loo, William P. Swaney, Travis E. Zeigler, Diana L. Nordling, Axel Schambach, Christopher Baum, David A. Williams, Punam Malik, and Lilith Reeves. Production of High-Titer GMP-Grade Retroviral Vectors by Transfection in a Closed System Bioreactor. Oral presentation at the 11th Annual Meeting of the American Society of Gene Therapy, May 28-June 1 (2008), Boston, MA, U.S.A.
Production of High Titer cGMP-Grade SIN Gamma-Retroviral Vectors by Transfection in a Closed System Bioreactor. Johannes C.M. van der Loo, William P. Swaney, Diana L. Nordling, Axel Schambach, Christopher Baum, David A Williams, Lilith Reeves, and Punam Malik. Poster presentation at the 50th American Society of Hematology Annual Meeting and Exposition, December 6-9, 2008, San Francisco, CA.
Production of Large-Scale Clinical-Grade SIN gamma-Retroviral Vector for the Treatment of X-linked SCID (X-SCID) by Transient Transfection. William P Swaney, Elke Grassman, Tomoyasu Higashimoto, Kathryn Mangopoulos, Michele Beuerlein, Diana L Nordling, Susan Buzun, Axel Schambach, Christopher Baum, David A Williams, Lilith Reeves, Punam Malik and Johannes C.M. Van der Loo. Poster presentation at the 12th Annual Meeting of the American Society of Gene Therapy, May 27 - 30, 2009, San Diego, CA.
Professional Organization Memberships
- American Society of Hematology
- International Society for Experimental Hematology
- American Socirty of Gene Therapy
- Association of Academic Biologics Manufacturers
Special Interests
The Vector Production Facility (cGMP; Director Han van der Loo), Cell Manipulation Laboratory (cGMP and cGTP; Director Diana Nordling), Translational Trials Support Laboratory (CAP/CLIA; Director Elke Grassman), and Viral Vector Core (Research; Director Han van der Loo) are part of the CCHMC Translational Core Laboratory (Director: Punam Malik) and provide a convenient one-stop shop for development, scale-up and clinical production of viral vectors and cellular products, and support of clinical gene transfer studies for early phase clinical trials under an Investigational New Drug (IND) application. Services are available to academia and industry, both national and international. To date, the VPF has produced cGMP Master Cell Banks (MCB), an Ad5 Master Viral Bank (MVB), gamma-Retroviral vectors and Adeno-Associated Virus (AAV) vectors in support of clinical studies in the US and Europe.
Related Areas
This person works in these other areas at Cincinnati Children's Hospital Medical
Center:
